nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

24.07.2018 | Original Article – Clinical Oncology

Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study

Complementary and alternative medicine in oncology

verfasst von: Claudia Bozza, Lorenzo Gerratana, Debora Basile, Maria Grazia Vitale, Michele Bartoletti, Elisa Agostinetto, Stefania Russo, Alessandro Follador, Elisa De Carlo, Nicoletta Pella, Roberta Sottile, Gianpiero Fasola, Fabio Puglisi

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

It is estimated that about half of cancer patients use at least one form of complementary and alternative medicines (CAM) in their life but there is a strong reticence of patients in talking about CAM with their oncologist. Primary aim of this study was to inform patients about CAM, focusing on their supposed benefits, toxicities and interactions with conventional therapeutic agents. The study also explored patients’ perception about CAM and ascertained the level of CAM use among cancer patients of an Italian academic hospital.

Methods

From April 2016 to April 2017, the observational pilot trial “CAMEO-PRO” prospectively enrolled 239 cancer patients that were invited to attend a tutorial about CAM at the Department of oncology, University Hospital of Udine, Italy. Before and after the informative session, patients were asked to fill a questionnaire reporting their knowledge and opinion about CAM.

Results

Overall, 163 (70%) women and 70 (30%) men were enrolled. Median age was 61 years. At study entry, 168 (72%) patients declared they had never been interested in this topic previously; 24 patients (11%) revealed the use of a type of alternative therapy and 58 (28%) revealed the use of complementary therapy. In total, 139 (55.2%) patients attended the informative session. Bowker’s test of symmetry demonstrated statistically significant opinion’s change after the session on 9 out of 14 explored items.

Conclusions

Informative sessions seem to have a relevant impact on patients’ perceptions and opinions about CAM.

Nur mit Berechtigung zugänglich

Ashar B, Vargo E (1996) Shark cartilage-induced hepatitis. Ann Intern Med 125:780–781CrossRef

Berretta M, Della Pepa C, Tralongo P et al (2017) Use of complementary and alternative medicine (CAM) in cancer patients: An Italian multicenter survey. Oncotarget 8:24401–24414PubMed

Bonacchi A, Fazzi L, Toccafondi A et al (2014) Use and perceived benefits of complementary therapies by cancer patients receiving conventional treatment in Italy. J Pain Symptom Manag 47:26–34CrossRef

Boon H, Stewart M, Kennard MA et al (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol Off J Am Soc Clin Oncol 18:2515–2521CrossRef

Boudreau MD, Beland FA (2006) An evaluation of the biological and toxicological properties of Aloe barbadensis (Miller), Aloe vera. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 24:103–154CrossRef

Bozza C, Agostinetto E, Gerratana L et al (2015) Complementary and alternative medicine in oncology. Recenti Prog Med 106:601–607PubMed

Budzinski JW, Foster BC, Vandenhoek S et al (2000) An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomed Int J Phytother Phytopharm 7:273–282

Burstein HJ, Gelber S, Guadagnoli E et al (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRef

Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575CrossRef

Ernst E (2002) The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 136:42–53CrossRef

Gansler T, Kaw C, Crammer C et al (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113:1048–1057CrossRef

Golden EB, Lam PY, Kardosh A et al (2009) Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 113:5927–5937CrossRef

Haller CA, Benowitz NL (2000) Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343:1833–1838CrossRef

Harris PE, Cooper KL, Relton C et al (2012) Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract 66:924–939CrossRef

Jatoi A, Ellison N, Burch PA et al (2003) A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97:1442–1446CrossRef

Kessler RC, Davis RB, Foster DF et al (2001) Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135:262–268CrossRef

Lee AH, Ingraham SE, Kopp M et al (2006) The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol 29:178–182CrossRef

MacGregor FB, Abernethy VE, Dahabra S et al (1989) Hepatotoxicity of herbal remedies. BMJ 299:1156–1157CrossRef

Metz JM, Jones H, Devine P et al (2001) Cancer patients use unconventional medical therapies far more frequently than standard history and physical examination suggest. Cancer J Sudbury Mass 7:149–154

Miller DR, Anderson GT, Stark JJ et al (1998) Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16:3649–3655CrossRef

Moertel CG, Fleming TR, Rubin J et al (1982) A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306:201–206CrossRef

Molassiotis A, Fernadez-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663CrossRef

Newell S, Sanson-Fisher RW (2000) Australian oncologists’ self-reported knowledge and attitudes about non-traditional therapies used by cancer patients. Med J Aust 172:110–113PubMed

Risberg T, Kaasa S, Wist E et al (1997) Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer Oxf Engl 1990 33:575–580

Saghatchian M, Bihan C, Chenailler C et al (2014) Exploring frontiers: use of complementary and alternative medicine among patients with early-stage breast cancer. Breast Edinb Scotl 23:279–285CrossRef

Schofield PE, Juraskova I, Butow PN (2003) How oncologists discuss complementary therapy use with their patients: an audio-tape audit. Support Care Cancer 11:348–355PubMed

Sparreboom A, Cox MC, Acharya MR et al (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489–2503CrossRef

Teschke R, Schwarzenboeck A, Eickhoff A et al (2013) Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 12:339–366CrossRef

Vaccini la bufala dei costi e degli incassi di Big pharma—Mondo Sanità—Blog—Repubblica.it. http://bocci.blogautore.repubblica.it/2017/06/24/vaccini-la-bufala-dei-costi-e-degli-incassi-di-big-pharma/. Accessed 30 June 2017

Yang HN, Kim DJ, Kim YM et al (2010) Aloe-induced toxic hepatitis. J Korean Med Sci 25:492–495CrossRef

Titel: Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study
Complementary and alternative medicine in oncology
verfasst von: Claudia Bozza
Lorenzo Gerratana
Debora Basile
Maria Grazia Vitale
Michele Bartoletti
Elisa Agostinetto
Stefania Russo
Alessandro Follador
Elisa De Carlo
Nicoletta Pella
Roberta Sottile
Gianpiero Fasola
Fabio Puglisi
Publikationsdatum: 24.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2709-2

Springer Medizin

Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study

Complementary and alternative medicine in oncology